Trial Profile
Phase II, Randomized, Open-label Study of the IGF-1R Inhibitor AXL1717 Compared to Docetaxel in Patients With Previously Treated, Locally Advanced, or Metastatic Squamous Cell Carcinoma or Adenocarcinoma of the Lung
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Picropodophyllin (Primary) ; Docetaxel
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Axelar
- 01 Mar 2017 Results published in the Acta Oncologica Journal.
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 02 Apr 2013 To date, 97 patients have been enrolled. The trial will be completed with about 100 patients, instead of the planned 140, because of the favourable interim outcomes.